AmericanPeptide
Catalog/Dermorphin

Dermorphin

Also known as [D-Ala2]-dermorphin

A potent, highly selective μ-opioid heptapeptide from amphibian skin — a research tool containing a D-amino acid.

Research refreshed

Overview

Dermorphin is a naturally occurring heptapeptide first isolated from the skin of South American Phyllomedusa frogs. It is a potent and highly selective agonist at the μ-opioid receptor, several times more potent than morphine by weight in animal assays, and it is notable biochemically for containing a D-amino acid (D-alanine at position 2) — one of the few vertebrate peptides to do so, which is what protects it from rapid enzymatic breakdown. It is used as a pharmacological research tool; it is a controlled-interest opioid compound and is not an approved medicine.

Background

Dermorphin is one of the classic examples of a vertebrate peptide that breaks the all-L rule: its second residue is D-alanine, incorporated post-translationally. That single stereochemical change makes the peptide resistant to the enzymes that would otherwise clear an opioid peptide quickly, and it is a textbook case for why D-amino acids matter in peptide design.

Pharmacologically it is a potent, selective μ-opioid agonist and is studied as a probe of opioid-receptor function and of peptide analgesia. Because it is a strong opioid, it is a research reagent rather than a wellness compound, and it has no approved therapeutic use. This page is a research and educational reference only.

Mechanism

High-affinity, selective μ-opioid-receptor agonism. The D-Ala2 residue and C-terminal amide confer resistance to peptidases, extending activity relative to all-L opioid peptides.

Key research findings

  • Selective μ-opioid agonist — potent and highly μ-selective in receptor and analgesia assays.
  • Contains a D-amino acid — D-Ala2 is a rare natural D-residue that confers peptidase resistance.
  • Research probe — used to study opioid-receptor pharmacology and peptide stability, not as a therapeutic.
  • Not approved — a controlled-interest research opioid with no approved medical use.

How Dermorphin is made

Behind every vial of Dermorphin is the same exacting pipeline every research peptide runs — but the chemistry plays out differently for this molecule. Here is how Dermorphin, specifically, is brought into being.

  1. On paper first

    On paper, Dermorphin is C40H50N8O10 — about 803.9 daltons of precisely arranged atoms. Before a single bond is made, the target sequence, salt form, and purity threshold are written down as the contract the finished material must meet.

  2. Built residue by residue

    Dermorphin is assembled by solid-phase peptide synthesis — the chain grows one protected residue at a time on resin, and what you fail to build cleanly here you pay to remove later.

  3. Purity is won here

    The crude mixture — Dermorphin plus its deletions and side products — is then separated on preparative HPLC, and where the cut is taken decides the difference between a genuinely pure peptide and a barely-passable one.

  4. Proven, then protected

    A real batch of Dermorphin proves itself: identity confirmed by mass spectrometry against its ~803.9 Da, purity read directly off an analytical HPLC trace, water and counterion content measured. That batch-specific certificate of analysis is the only honest way to know what is actually in a vial of Dermorphin — and a short, cold, accountable chain of custody is how that purity survives the trip to your bench.

Walk the full synthesis pipeline

Handling, storage & why purity is hard

A heptapeptide amide whose defining synthetic feature is a D-alanine at position 2 — built by solid-phase synthesis with an Fmoc-D-Ala building block and a C-terminal amide from Rink-amide resin. The D-residue is what resists peptidases; over a seven-residue chain, deletion-sequence removal sets the purity, and identity work must confirm the D-configuration rather than assume the all-L sequence.

Storage
Store lyophilized, frozen, and protected from light; keep reconstituted peptide refrigerated and use within a short window. As a potent opioid research reagent, it also warrants controlled, labeled, restricted-access storage.
Handling
Handle as a high-potency compound with appropriate PPE, and verify the D-Ala2 configuration by analysis — an all-L impurity is a different, less stable molecule than dermorphin.

Don't judge a vial by its cake. A fluffy, good-looking lyophilized powder reflects bulking agents and freeze-drying parameters — not purity. Insist on a batch-specific certificate of analysis.

How peptides are made — the full pipeline

Research areas

  • Opioid-receptor pharmacology
  • Analgesia research
  • Peptide stability (D-amino acids)

Latest research

Recent clinical trials and publications mentioning Dermorphin, pulled automatically from ClinicalTrials.gov and PubMed and refreshed daily. Listings are unfiltered search results, not curated endorsements.

Frequently asked questions

What is dermorphin?+

A heptapeptide from amphibian skin that is a potent, selective μ-opioid-receptor agonist, used as a research tool. It contains a rare D-amino acid (D-Ala2).

Why does the D-amino acid matter?+

The D-alanine at position 2 resists enzymatic breakdown, which both extends the peptide’s activity and makes it a classic example of D-amino-acid stabilization in peptide design.

Is it used clinically?+

No — it is a potent opioid studied as a research reagent, with no approved therapeutic use.

Is it approved?+

No. This page is a research and educational reference, not medical advice.

Related peptides

Peptide Agent

Ask the Agent about Dermorphin

Dosing protocols, mechanism, comparisons, and the latest trials — citation-backed answers grounded in PubMed, PubChem, and ClinicalTrials.gov.